A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer Lawrence Cohen, CEO 77 Water Street , Suite 817 New York, NY 10005 Lawrence.Cohen@Glycotest.com +1 646-354-8361 www.glycotest.com

Series A Financing Closed Fosun Pharma and NetScientific plc investors $10MM equity investment $3MM on close $7MM on completion of certain milestones Subject to Chinese ODI and US CFIUS approval Fosun receives: 40% equity stake in Glycotest Exclusive license for China to the Glycotest HCC Panel early-stage liver cancer test Glycotest earns royalty on sales in China Glycotest will use proceeds to: Launch the HCC Panel in the US Transfer HCC Panel technology to Fosun Further develop pipeline tests for liver fibrosis and cholangiocarcinoma

Glycotest The Company Founded 2012 on technology innovated at the Baruch S. Blumberg Institute and Drexel University College of Medicine (Philadelphia) Glycotest technology has benefitted from $8.9MM in grants to the innovators Proprietary blood-based biomarkers, panels and algorithms for the surveillance of patients at high risk of serious liver disease Five US and eight ex-US patents issued or allowed covering >50 novel glycoprotein biomarkers; additional patents pending Focused on liver cancer and fibrosis surveillance Commercial clinical laboratory services for patients at risk for liver cancers and fibrosis >$1B opportunity—huge and growing populations with viral and non-viral hepatitis driving progressive fibrosis and liver cancer risk Lead product—biomarker panel for hepatocellular carcinoma (HCC Panel) to surveil patients at risk for predominant form of primary liver cancer

> $1B HCC Panel Market Opportunity Huge and growing populations with viral and non-viral hepatitis—driving progressive fibrosis, liver cancer risk and need for effective disease surveillance Chronic hepatitis B: 2.2 MM US; 360 MM WW; incurable Chronic hepatitis C: 3.2 MM US; 170 MM WW; liver cancer risk persists despite cure Fatty liver disease and NASH / ASH: >100 MM US; >1.5 B WW; rapidly growing populations due to obesity and metabolic disease Cirrhosis: 3.2 MM US; 73 MM WW; secondary to hepatitis; proximate cause of most liver cancer Estimated market value for the HCC Panel is $818 MM in the US alone Assumes only 620,000 US patients under surveillance—20% of 3.1 MM eligible patients In China… > 350,000 people die of liver cancer each year > 350MM people at risk for liver cancer due to serious liver disease—viral hepatitis, fatty liver disease and NASH, alcoholic liver disease and ASH Liver cancer surveillance drives lower healthcare costs Early detection of HCC enables lower cost curative therapy—resection or ablation Later stage HCC is only eligible for higher cost palliative therapy—TACE or chemotherapy Cost effective HCC panel will enable early-stage HCC detection, lower cost treatment options, and better patient outcomes that will drive market adoption

Lead Product—HCC Panel Algorithm-driven panel—surveillance for curable HCC To detect curable early-stage disease To provide a convenient blood test that guides CT / MRI confirmation For patients at risk due to both viral and non-viral hepatitis Early-stage HCC is curable Resection and ablation lead to long-term disease free survival Curative treatment is less costly than palliative care for later stage disease Current blood tests and imaging modalities have low sensitivity and/or specificity—curable early-stage disease is being missed Large and expanding population needs an effective HCC surveillance solution Cirrhosis + chronic hepatitis B w/o cirrhosis—3.1 MM US; 323 MM WW NASH pandemic expanding market Chronic testing opportunity—repeat testing every 3-6 months Glycotest’s HCC Panel significantly outperforms currently dominant blood test (AFP) in three clinical studies involving >480 patients

HCC Panel Technology and Clinical Performance Glycotest’s proprietary HCC Panel relies on novel glycoprotein biomarkers Unique abnormal change in sugar structure in liver disease— core fucose disease signal Data from three head-to-head clinical studies in >480 patients demonstrate performance superior to AFP, the currently dominant blood test for HCC surveillance